The Scientist - USA (2020-05)

COMINGSOON

Leveraging Advances in Predesigned Synthetic sgRNAs for

Highly Functional and Specific CRISPR-Cas9 Gene Knockout

WEBINAR SPONSORED BY

Each individual tumor is unique, carrying its own distinguishing antigens, which can complicate the cancer vaccine development process. Cancer vaccines

target unique tumor antigens, including overexpressed healthy proteins or virus-derived proteins. To better characterize, identify, and understand the

dynamic interactions between the immune system and cancer cell antigens, researchers can turn to advanced flow cytometry and live-cell imaging

technologies. This webinar, brought to you by The Scientist and sponsored by Sartorius, will present new research and developments in the cancer vaccine

field and delve into the intricacies of target discovery and vaccine development.

CRISPR-based genome editing has accelerated biological research and introduced great potential for studying and treating human diseases. The

CRISPR-Cas9 system requires a Cas9 nuclease and a guide RNA, which may consist of either a CRISPR RNA (crRNA) coupled with a trans-activating

crRNA (tracrRNA), or a single guide RNA (sgRNA) that combines the crRNA and tracrRNA in a single molecule. Both guide RNA formats can be

chemically synthesized, offering advantages over expression systems. This webinar, sponsored by Horizon Discovery, will explain how synthetic guide

RNAs are amenable to chemical modifications for increased stability, eliminate time-consuming steps of cloning and sequencing, and do not evoke

the inherent immune response and cytotoxicity that accompanies in vitro transcribed guide RNAs. They can be readily delivered into cells for high-

throughput arrayed screening applications to expand the types of phenotypic readouts to high-content and morphology-based assays.

DAVID E. AVIGAN, MD

Professor of Medicine

Beth Israel Deaconess Medical Center

KURT MARSHALL, PhD

R&D Scientist

Horizon Discovery

MARY L. (NORA) DISIS, MD

Helen B. Slonaker Endowed Professor

for Cancer Research

American Cancer Society Clinical

Research Professor

Professor, Medicine, Adjunct Professor Pathology

and Obstetrics and Gynecology,

University of Washington

Director, UW Medicine Cancer Vaccine Institute

THURSDAY, MA Y 21, 2020

2:30 - 4:00 PM EST

REGISTER NOW!

http://www.the-scientist.com/cancer-vaccines

REGISTER NOW!

http://www.the-scientist.com/synthetic-sgrna-crispr-

cas-knockout-horizon-discovery

TOPICS TO BE COVERED

• Developing breast cancer vaccines with dendritic
  cell tumor fusions


• Boosting immunity with cancer vaccines: A focus
  on breast and ovarian cancer immunology

TOPICS TO BE COVERED

• How to use Edit-R Synthetic sgRNA for robust CRISPR
  gene knockout


• Functionality of sgRNA in different cell models, including
  primary T cells


• Simplifying high-throughput loss-of-function screening
  with sgRNAs

COMINGSOON Advancing Cancer Vaccines

TUESDAY, MA Y 12, 2020

2:30 - 4:00 PM EST

WEBINAR SPONSORED BY